Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Next Previous
Trial Profile

A Phase Ib Study of Guadecitabine (SGI-110) and Durvalumab (MEDI 4736) in Patients With Advanced Hepatocellular Carcinoma, Pancreatic Adenocarcinoma, and Cholangiocarcinoma/Gallbladder Cancer

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Aug 2018

At a glance

  • Drugs Durvalumab (Primary) ; Guadecitabine (Primary)
  • Indications Adenocarcinoma; Cholangiocarcinoma; Gallbladder cancer; Liver cancer; Pancreatic cancer
  • Focus Adverse reactions; Therapeutic Use

    • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 27 Mar 2018 Planned End Date changed from 18 Dec 2020 to 20 Feb 2020.
    • 27 Mar 2018 Planned primary completion date changed from 18 Dec 2019 to 7 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top